DUBLIN--(BUSINESS WIRE)--The 'Cell and Gene Therapy Deals Analysis, 2021-2024' report has been added to ResearchAndMarkets.com's offering.

都柏林--（商业新闻短讯）--“细胞与基因治疗交易分析，2021-2024”报告已添加到ResearchAndMarkets.com的产品中。

The Cell and Gene Therapy Deals Analysis offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field..

细胞和基因治疗交易分析全面审视了动态且快速发展的细胞和基因治疗市场。本报告重点介绍了2021年第1季度至2024年第1季度发生的重大交易活动，为希望了解和利用这一新兴领域趋势的公司和利益相关者提供了宝贵的见解。。

With cell and gene therapy becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

随着细胞和基因治疗成为一个竞争激烈的市场，本报告特别提到了1000多家公司。

With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. The report provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry..

随着1500多家公司积极参与细胞和基因治疗领域，了解趋势和竞争格局对于战略规划至关重要。该报告提供了在这个快速增长的行业中导航和利用机会所需的基本市场分析。。

Report Highlights:

报告亮点：

Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.

季度资金趋势（2021年第1季度至2024年第1季度）：资金金额的图形表示，显示细胞和基因治疗的投资流入。

Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.

交易类型：对2000多项交易进行全面分类，包括风险投资、私人投资、合并、收购、战略合作、许可、制造/供应和分销/联合营销。

Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.

顶级交易制定者：根据交易类型和整体交易活动确定最活跃的公司。

Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.

区域交易细分：对不同区域的交易制定活动进行百分比分析。

The report is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

该报告旨在为进入或已经进入该市场的公司提供有关交易趋势的知识，这些交易将影响未来的增长和竞争。

The following is just some of the information in this report:

以下是本报告中的部分信息：

Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region

2021年第1季度至2024年第1季度按类型和地区划分的季度融资金额

Specific details of 2000+ CGT Deals

2000多笔CGT交易的具体细节

Venture Capital/Private Funding Round Amounts, By Quarter

按季度划分的风险资本/私人融资总额

Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)

多个类别（风险投资、并购和其他领域）的时间趋势

Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation.

按类型划分的交易-技术/研究/战略合作；风险投资/私人投资；收购、兼并、战略投资；许可；公开募股/SPAC；制造、供应链；分销、联合营销；分拆、重组；达成/终止交易；合资企业；并解决诉讼。

Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)

按交易类型（收购/合并/战略投资、整体交易、合作）划分的最活跃的交易公司

Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

交易达成的地区细分[北美、欧洲、亚太地区和世界其他地区]（%）

Key Topics Covered:

涵盖的关键主题：

Chapter 1: Executive Summary

第一章：执行摘要

$35 Billion in Investment in 2023

2023年投资350亿美元

Quarterly Funding Amounts

季度资金金额

Quarterly Funding Category Shares, Q1 2021 Through Q1 2024

2021年第1季度至2024年第1季度季度融资类股票

Quarterly Deal Counts by Category, Q1 2021 - Q1 2024

2021年第1季度至2024年第1季度按类别划分的季度交易数量

Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy

合作、制造/供应链交易、许可、分销/共同营销的增长突出了细胞和基因治疗的活动

A Look at Less Frequent CGT Deal Types

看看不太常见的CGT交易类型

Most Active Companies

最活跃的公司

Chapter 2: Venture Capital & Private Funding

第二章：风险投资与私人融资

VC/Private Funding in Flux

不断变化的风险投资/私人资金

Chapter 3: Strategic Investments

第三章：战略投资

Strategic Investments in Cell and Gene Therapy

细胞和基因治疗的战略投资

Chapter 4: IPOs, FPOs, & SPACs

第4章：IPO、FPO和SPAC

North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs

北美的大部分收益来自IPO、FPO、SPAC

Chapter 5: Mergers & Acquisitions (M&A)

第五章：并购

Growing Numbers of M&A, Despite Lower Average Value

尽管平均价值较低，但并购数量仍在增加

Chapter 6: Technology/Research/Strategic Collaborations

第6章：技术/研究/战略合作

CGT Market Sees a Broad Variety of Collaborations

CGT市场有各种各样的合作

Chapter 7: Licensing

第7章：许可

Stable Levels of Licensing in the Cell and Gene Therapy Market

细胞和基因治疗市场的许可水平稳定

Chapter 8: Manufacturing and Supply Chain

第8章：制造和供应链

Major Growth in Manufacturing and Supply Chain Management Activity in CGT

CGT制造业和供应链管理活动大幅增长

Chapter 9: Distribution & Co-Marketing

第9章：分销与联合营销

A Look at CGT Distribution and Co-Marketing Deals

CGT分销和联合营销协议

Chapter 10: Other - JV, Restructuring, Termination, Spinoffs

第10章：其他-合资企业、重组、终止、分拆

A Look at Other Types of Deals Impacting Cell and Gene Therapy

看看影响细胞和基因治疗的其他类型的交易

For more information about this report visit https://www.researchandmarkets.com/r/qho56a

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/qho56a

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。